[go: up one dir, main page]

CL2017001119A1 - Unidad de fármaco-dispositivo que contiene quinagolida - Google Patents

Unidad de fármaco-dispositivo que contiene quinagolida

Info

Publication number
CL2017001119A1
CL2017001119A1 CL2017001119A CL2017001119A CL2017001119A1 CL 2017001119 A1 CL2017001119 A1 CL 2017001119A1 CL 2017001119 A CL2017001119 A CL 2017001119A CL 2017001119 A CL2017001119 A CL 2017001119A CL 2017001119 A1 CL2017001119 A1 CL 2017001119A1
Authority
CL
Chile
Prior art keywords
drug
unit
polymeric
diffunctional
alkylene oxide
Prior art date
Application number
CL2017001119A
Other languages
English (en)
Inventor
Janet Halliday
Denis Carr
Alistair Ross
Claire Young
Paul Mcdonald
Mohammad Qadir
Robert Cochrane
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2017001119A1 publication Critical patent/CL2017001119A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001—Combinations of extrusion moulding with other shaping operations
    • B29C48/0021—Combinations of extrusion moulding with other shaping operations combined with joining, lining or laminating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor
    • B29L2031/754—Pessaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE BASA EN LA IDENTIFICACIÓN DE UNA COHORTE DE COPOLÍMEROS DE BLOQUES DE POLIURETANO QUE SON PARTICULARMENTE ADECUADOS PARA SU USO EN UNIDADES POLIMÉRICAS Y FARMACÉUTICAS DE FÁRMACO-DISPOSITIVO Y ÉSTOS OFRECEN UN CONTROL MEJORADO DE LA LIBERACIÓN DEL FÁRMACO. ESPECÍFICAMENTE, SE PROVEE UNA UNIDAD POLIMÉRICA DE FÁRMACO-DISPOSITIVO QUE COMPRENDE UNO COPOLÍMERO DE BLOQUE DE POLIURETANO FORMADO AL REACCIONAR JUNTOS, UN POLI(ÓXIDO DE ALQUILENO), UN COMPUESTO DIFUNCIONAL, UN ISOCIANATO DIFUNCIONAL Y OPCIONALMENTE UN COPOLIMERO DE BLOQUE QUE COMPRENDE BLOQUE DE POLI(ÓXIDO DE ALQUILENO); Y QUINAGOLIDA O COMO AGENTE FARMACÉUTICAMENTE ACTIVO. LA UNIDAD POLIMÉRICA DE FÁRMACO-DISPOSITIVO SE ENCONTRÓ APLICABLE EN EL TRATAMIENTO Y/O PREVENCIÓN DE LA ENDOMETRIOSIS.</p>
CL2017001119A 2014-11-07 2017-05-05 Unidad de fármaco-dispositivo que contiene quinagolida CL2017001119A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14192372.2A EP3017809A1 (en) 2014-11-07 2014-11-07 Drug-device unit containing quinagolide

Publications (1)

Publication Number Publication Date
CL2017001119A1 true CL2017001119A1 (es) 2018-01-05

Family

ID=51951583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001119A CL2017001119A1 (es) 2014-11-07 2017-05-05 Unidad de fármaco-dispositivo que contiene quinagolida

Country Status (34)

Country Link
US (2) US20180008535A1 (es)
EP (3) EP3017809A1 (es)
JP (2) JP6907120B2 (es)
KR (1) KR102612852B1 (es)
CN (2) CN106999422A (es)
AR (1) AR102571A1 (es)
AU (2) AU2015341734C1 (es)
CA (1) CA2966473A1 (es)
CL (1) CL2017001119A1 (es)
CO (1) CO2017005578A2 (es)
DK (1) DK3215118T3 (es)
EA (2) EA033806B9 (es)
ES (1) ES2877973T3 (es)
HR (1) HRP20210961T1 (es)
HU (1) HUE054951T2 (es)
IL (1) IL252088B (es)
JO (1) JO3561B1 (es)
LT (1) LT3215118T (es)
MA (2) MA40897B1 (es)
MD (1) MD3215118T2 (es)
MX (1) MX379298B (es)
MY (1) MY193638A (es)
NZ (1) NZ731763A (es)
PH (1) PH12017550005A1 (es)
PL (1) PL3215118T3 (es)
PT (1) PT3215118T (es)
RS (1) RS62018B1 (es)
SA (1) SA517381471B1 (es)
SG (1) SG11201703596SA (es)
SI (1) SI3215118T1 (es)
TN (1) TN2017000175A1 (es)
TW (1) TWI685339B (es)
UA (1) UA122329C2 (es)
WO (1) WO2016071466A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091456A1 (ko) 2018-10-31 2020-05-07 ㈜아모레퍼시픽 바이오 폴리머를 포함하는 코어-쉘 네트워크 구조체 및 이를 포함하는 조성물
KR20210069344A (ko) 2019-12-03 2021-06-11 (주)아모레퍼시픽 바이오 폴리머를 포함하는 효능물질 전달체
US20240361338A1 (en) 2021-08-31 2024-10-31 Ferring B.V. Diagnosis and treatment of ectopic endometriosis
WO2024153752A1 (en) 2023-01-20 2024-07-25 Ferring B.V. Stereoselective synthesis of intermediates and synthesis of quinagolids
WO2025093626A1 (en) * 2023-10-31 2025-05-08 Basf Se Process for producing thermoplastic polyurethanes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
ES2442675T3 (es) 2003-07-10 2014-02-12 Warner Chilcott (Ireland) Limited Dispositivos intravaginales de suministro de fármacos
US8784874B2 (en) * 2003-09-10 2014-07-22 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
DE602006015796D1 (de) 2005-04-29 2010-09-09 Ferring Int Ct Sa Behandlung oder vorbeugung des ovariellen überstimulationssyndroms (ohss) mit einem dopaminagonisten
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
KR20100120665A (ko) 2008-01-25 2010-11-16 더 유니버시티 오브 유타 리서치 파운데이션 일차 방출 중합체
JP5774853B2 (ja) * 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
CA2765997A1 (en) * 2009-06-26 2010-12-29 Ferring B.V. Treatment of endometriosis
JP2013525285A (ja) * 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート 化合物の送達を増強するための方法および組成物
ES2728975T3 (es) 2010-11-15 2019-10-29 Dsm Ip Assets Bv Dispositivo intravaginal de aporte de fármacos que comprende un copolímero de poliuretano
WO2013013172A1 (en) * 2011-07-20 2013-01-24 The University Of Utah Research Foundation Intravaginal devices for drug delivery
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
CO2017005578A2 (es) 2017-08-31
IL252088B (en) 2022-04-01
US20180008535A1 (en) 2018-01-11
CN106999422A (zh) 2017-08-01
EA201790898A8 (ru) 2018-01-31
HRP20210961T1 (hr) 2021-09-17
MX379298B (es) 2025-03-10
SI3215118T1 (sl) 2021-08-31
EP3892261A1 (en) 2021-10-13
AU2015341734B2 (en) 2020-08-20
WO2016071466A1 (en) 2016-05-12
SA517381471B1 (ar) 2022-03-06
AU2015341734C1 (en) 2020-12-17
LT3215118T (lt) 2021-06-10
DK3215118T3 (da) 2021-06-21
EP3215118A1 (en) 2017-09-13
IL252088A0 (en) 2017-07-31
KR20170080671A (ko) 2017-07-10
MY193638A (en) 2022-10-21
MA56414A (fr) 2022-05-04
BR112017009476A2 (en) 2018-01-02
PH12017550005A1 (en) 2017-10-18
EA201790898A1 (ru) 2017-11-30
JP2017533272A (ja) 2017-11-09
CN116212032A (zh) 2023-06-06
TWI685339B (zh) 2020-02-21
UA122329C2 (uk) 2020-10-26
NZ731763A (en) 2024-04-26
MA40897B1 (fr) 2021-04-30
EA033806B9 (ru) 2019-12-19
ES2877973T3 (es) 2021-11-17
PT3215118T (pt) 2021-05-31
JP2021155444A (ja) 2021-10-07
EP3017809A1 (en) 2016-05-11
AU2020270480A1 (en) 2020-12-17
SG11201703596SA (en) 2017-06-29
MD3215118T2 (ro) 2021-08-31
TN2017000175A1 (en) 2018-10-19
CA2966473A1 (en) 2016-05-12
KR102612852B1 (ko) 2023-12-11
JP6907120B2 (ja) 2021-07-21
HUE054951T2 (hu) 2021-10-28
PL3215118T3 (pl) 2021-07-26
AU2015341734A1 (en) 2017-06-01
EA201991882A2 (ru) 2020-01-31
MX2017005828A (es) 2017-11-13
MA40897A (fr) 2017-09-13
TW201625245A (zh) 2016-07-16
EP3215118B1 (en) 2021-03-17
RS62018B1 (sr) 2021-07-30
AR102571A1 (es) 2017-03-08
US20220040094A1 (en) 2022-02-10
JO3561B1 (ar) 2020-07-05
EA033806B1 (ru) 2019-11-27

Similar Documents

Publication Publication Date Title
CL2017001119A1 (es) Unidad de fármaco-dispositivo que contiene quinagolida
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX378273B (es) Compuestos activos hacia bromodominios.
MX386427B (es) Sistemas y métodos para cicatrización de tejido.
CO2017010894A2 (es) Cuerpo mixto novedoso de compuesto de hierro y óxido de grafeno
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
CL2015002897A1 (es) Inhibidores de bace1
PH12017501806A1 (en) Anthelmintic combinations and methods of use thereof
CL2015001574A1 (es) Terapia combinada para el cancer
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2019001335A (es) Medicamento para el tratamiento y/o prevencion de endometriosis.
UA101950U (uk) Фармацевтична композиція для лікування і профілактики застуди
CL2016000822A1 (es) Tratamiento del cáncer con una combinación de plinabulina y taxano
UA100460U (uk) Застосування препарату ноофен як засобу лікування еректильної дисфункції в моно- або комплексній терапії
IT201600069689U1 (it) Benda elastica, particolarmente per l’impiego nel trattamento del flebo-linfoedema.
UA101951U (uk) Фармацевтична композиція для лікування і профілактики застуди
CL2016000893A1 (es) Sistema de administración intrauterina que comprende una construcción de un cuerpo y dos depósitos, los cuales comprenden un progestágeno donde los depósitos tienen velocidades y tiempos de liberación diferentes
CL2015003702A1 (es) Formulación farmacéutica en forma de micropartículas estériles, que comprenden como agente activo rhein, y copolímeros del ácido láctico y glicólico (plga). proceso de elaboración y uso en pacientes que presentan patologías articulares.